A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. (January 2018)

• Record Type: Journal Article
• Authors: Moore, Kathleen N; Martin, Lainie P; O'Malley, David M; Matulonis, Ursula A; Konner, Jason A; Vergote, Ignace; Ponte, Jose F; Birrer, Michael J
• Is Part Of: Future oncology. Volume 14:Number 2(2018)
• Page Start: 123
• Page End: 136
• Publication Date: 2018-01
• Subjects: antibody–drug conjugate -- folate receptor-α -- mirvetuximab soravtansine -- novel therapy -- ovarian cancer -- platinum resistance; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0379
• Languages: English
• ISSNs: 1479-6694

Abstract

Resistance to platinum-based therapy poses a significant clinical challenge for the management of advanced ovarian cancer, a leading cause of cancer mortality among women. Mirvetuximab soravtansine is a novel antibody–drug conjugate that targets folate receptor-α, a validated molecular target for therapeutic intervention in this disease. Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date. We focus on the favorable tolerability and encouraging signals of efficacy that have emerged, most notably in patients with platinum-resistant disease. Ongoing Phase III monotherapy and Phase Ib/II combination trials evaluating its activity in the setting of platinum resistance are emphasized, which will help define its role in the evolving landscape of ovarian cancer therapy.